Source: Reuters
Area: News
According to a Reuters report, the Southampton, Hampshire, Isle of Wight and Portsmouth Primary Care Trust Cluster has discontinued its policy of offering intravitreal bevacizumab, an unlicensed but cheaper treatment for the treatment of wet age-related macular degeneration.
This follow a legal challenge from Novartis, the manufacturers of ranibizumab (LucentisT), a licensed treatment for wet age-related macular degeneration. Novartis have previously argued that the use of bevacizumab off-label could put patients at risk of adverse effects (see previous NELM report below).
The health authority (Read more...)
Uncategorized